Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249698 | 0.89 | MAPT (0.43) | SCN8ASCN10AMAPTHCRTR1HCRTR2 | |
| SCHEMBL14760908 | 0.87 | MAPT (0.41) | SCN8ASCN10AMAPTHCRTR1HCRTR2 | |
| SCHEMBL6364181 | 0.85 | POLQ (0.41) | SCN8ASCN10AGPBAR1MAPTHCRTR1 | |
| SCHEMBL6959867 | 0.79 | MAPT (0.37) | MAPTHCRTR1HCRTR2PTGDR2ERAP1 | |
| SCHEMBL13388895 | 0.78 | MAPT (0.43) | CYP1A2CYP3A4CYP2C19MAPTHCRTR1 | |
| SCHEMBL13388545 | 0.78 | MAPT (0.43) | SCN8ASCN10AMAPTHCRTR1HCRTR2 | |
| SCHEMBL6552186 | 0.77 | CES2 (0.45) | — | |
| SCHEMBL6114202 | 0.76 | MAPT (0.43) | SCN8ASCN10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27151678 | 0.75 | MAPT (0.36) | GPBAR1CYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL1513789 | 0.74 | ERAP1 (0.47) | MAPTERAP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | claimed |
| WO-2005032551-A1 | TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | SCN8A 4593/4885SCN10A 4683/4885GPBAR1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.